The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Technological and practical challenges of dry powder inhalers and formulations
Open accessAbstract
In the 50 years following the introduction of the first dry powder inhaler to the market, several developments have occurred. Multiple-unit dose and multi-dose devices have been introduced, but first generation capsule inhalers are still widely used for new formulations. Many new particle engineering techniques have been developed and considerable effort has been put in understanding the mechanisms that control particle interaction and powder dispersion during inhalation. Yet, several misconceptions about optimal inhaler performance manage to survive in modern literature. It is, for example still widely believed that a flow rate independent fine particle fraction contributes to an inhalation performance independent therapy, that dry powder inhalers perform best at 4 kPa (or 60 L/min) and that a high resistance device cannot be operated correctly by patients with reduced lung function. Nevertheless, there seems to be a great future for dry powder inhalation. Many new areas of interest for dry powder inhalation are explored and with the assistance of new techniques like computational fluid dynamics and emerging particle engineering technologies, this is likely to result in a new generation of inhaler devices and formulations, that will enable the introduction of new therapies based on inhaled medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raaschou-Nielsen, O., Andersen, Z. J., Beelen, R., Samoli, E., Stafoggia, M., Weinmayr, G., Hoffmann, B., Fischer, P., Nieuwenhuijsen, M. J., Brunekreef, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70279-1 · Cited by 1,582
Labiris, N. R., & Dolovich, M. B. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01892.x · Cited by 1,245
Large Porous Particles for Pulmonary Drug Delivery
Edwards, D. A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M. L., Mintzes, J., Deaver, D., Lotan, N., & Langer, R. (1997) · Science · doi:10.1126/science.276.5320.1868 · Cited by 1,174
What the pulmonary specialist should know about the new inhalation therapies
Laube, B. L., Janssens, H. M., de Jongh, F. H. C., Devadason, S. G., Dhand, R., Diot, P., Everard, M. L., Horvath, I., Navalesi, P., Voshaar, T., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00166410 · Cited by 806
Inadequate Literacy Is a Barrier to Asthma Knowledge and Self-Care
Williams, M. V., Baker, D. W., Honig, E. G., Lee, T. M., & Nowlan, A. (1998) · Chest · doi:10.1378/chest.114.4.1008 · Cited by 660
Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD
Lavorini, F., Magnan, A., Christophe Dubus, J., Voshaar, T., Corbetta, L., Broeders, M., Dekhuijzen, R., Sanchis, J., Viejo, J. L., Barnes, P., et al. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2007.11.003 · Cited by 609
Regional Lung Deposition and Bronchodilator Response as a Function of β 2 -Agonist Particle Size
Usmani, O. S., Biddiscombe, M. F., & Barnes, P. J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1414oc · Cited by 578
Aerosol drug delivery: developments in device design and clinical use
Dolovich, M. B., & Dhand, R. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60926-9 · Cited by 505
Dry Powder Inhaler Formulation
Telko, M. J., & Hickey, A. J. (2005) · Respiratory Care · doi:10.4187/respcare.05501209 · Cited by 498
Kottmann, R. M., Kulkarni, A. A., Smolnycki, K. A., Lyda, E., Dahanayake, T., Salibi, R., Honnons, S., Jones, C., Isern, N. G., Hu, J. Z., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201201-0084oc · Cited by 415
Recent advances in pulmonary drug delivery using large, porous inhaled particles
Edwards, D. A., Ben-Jebria, A., & Langer, R. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.2.379 · Cited by 341
Drug delivery to the respiratory tract using dry powder inhalers
Timsina, M. P., Martin, G. P., Marriott, C., Ganderton, D., & Yianneskis, M. (1994) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)90070-1 · Cited by 325
Formulation and Physical Characterization of Large Porous Particles for Inhalation
Vanbever, R., Mintzes, J. D., Wang, J., Nice, J., Chen, D., Batycky, R., Langer, R., & Edwards, D. A. (1999) · Pharmaceutical Research · doi:10.1023/a:1018910200420 · Cited by 314
Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology
Geller, D. E., Weers, J., & Heuerding, S. (2011) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2010.0855 · Cited by 308
Particle engineering techniques for inhaled biopharmaceuticals
Shoyele, S. A., & Cawthorne, S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.010 · Cited by 301
Dry powder inhalers for pulmonary drug delivery
Frijlink, H. W., & De Boer, A. H. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.67 · Cited by 259
Self-citationRecent Advances in Novel Drug Carrier Systems
(2012) · InTech eBooks · doi:10.5772/2889 · Cited by 247
Rootmensen, G. N., van Keimpema, A. R. J., Jansen, H. M., & de Haan, R. J. (2010) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2009.0785 · Cited by 231
Distribution of Receptor Targets in the Lung
Barnes, P. J. (2004) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200409-045ms · Cited by 213
Schuster, A., Haliburn, C., Döring, G., Goldman, M. H., & for the Freedom Study Group (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202059 · Cited by 208
Dry Powder Aerosols I: A New Powder Inhalation Device
Bell, J. H., Hartley, P. S., & Cox, J. S. G. (1971) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600601028 · Cited by 202
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201
Inhalation therapy: an historical review
Sanders, M. (2007) · Primary Care Respiratory Journal · doi:10.3132/pcrj.2007.00017 · Cited by 199
Poor inhalation technique, even after inhalation instructions, in children with asthma
Kamps, A. W. A., van Ewijk, B., Roorda, R. J., & Brand, P. L. P. (2000) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(200001)29:1<39::aid-ppul7>3.0.co;2-g · Cited by 197
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
Geller, D. E., Konstan, M. W., Smith, J., Noonberg, S. B., & Conrad, C. (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20594 · Cited by 196
Coates, M. S., Fletcher, D. F., Chan, H.-K., & Raper, J. A. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20201 · Cited by 196
Jones, M. D., & Price, R. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9012-7 · Cited by 193
Clinical Pharmacokinetics and Pharmacodynamics of Inhaled Insulin
Patton, J. S., Bukar, J. G., & Eldon, M. A. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443120-00002 · Cited by 188
Small Airway Disease in Asthma and COPD
van den Berge, M., ten Hacken, N. H. T., Cohen, J., Douma, W. R., & Postma, D. S. (2011) · Chest · doi:10.1378/chest.10-1210 · Cited by 186
Calculated deposition of inhaled particles in the airway generations of normal subjects
Gerrity, T. R., Lee, P. S., Hass, F. J., Marinelli, A., Werner, P., & Lourenco, R. V. (1979) · Journal of Applied Physiology · doi:10.1152/jappl.1979.47.4.867 · Cited by 180
Hollow Porous Particles in Metered Dose Inhalers
Dellamary, L. A., Tarara, T. E., Smith, D. J., Woelk, C. H., Adractas, A., Costello, M. L., Gill, H., & Weers, J. G. (2000) · Pharmaceutical Research · doi:10.1023/a:1007513213292 · Cited by 179
Alternative sugars as potential carriers for dry powder inhalations
Steckel, H., & Bolzen, N. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.10.039 · Cited by 176
de Boer, A. H., Chan, H. K., & Price, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.04.004 · Cited by 162
Self-citationTherapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Willis, L., Hayes, D., & Mansour, H. M. (2012) · Lung · doi:10.1007/s00408-011-9360-x · Cited by 148
Controlled Release Pulmonary Administration of Curcumin Using Swellable Biocompatible Microparticles
El-sherbiny, I. M., & Smyth, H. D. C. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200351y · Cited by 144
Deagglomeration of dry powder pharmaceutical aerosols
Voss, A., & Finlay, W. H. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00319-8 · Cited by 143
Coates, M. S., Chan, H., Fletcher, D. F., & Raper, J. A. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20603 · Cited by 138
Inhaled therapy in elderly COPD patients; time for re-evaluation?
Jarvis, S., Ind, P. W., & Shiner, R. J. (2007) · Age and Ageing · doi:10.1093/ageing/afl174 · Cited by 134
Young, P. M., Cocconi, D., Colombo, P., Bettini, R., Price, R., Steele, D. F., & Tobyn, M. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/002235702760345400 · Cited by 130
Latest advances in the development of dry powder inhalers
Ashurst, I., Malton, A., Prime, D., & SUMBY, B. S. (2000) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(00)00275-3 · Cited by 128
Barrons, R., Pegram, A. H., & Borries, A. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100452 · Cited by 128
Karner, S., & Urbanetz, N. A. (2011) · Journal of Aerosol Science · doi:10.1016/j.jaerosci.2011.02.010 · Cited by 118
Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma
Bisgaard, H. F., Klug, B. H., SUMBY, B. S., & Burnell, P. K. P. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.11051111 · Cited by 117
Jebria, A. B., Chen, D., Eskew, M. L., Rita Vanbever, A., Langer, R., & Edwards, D. A. (1999) · Pharmaceutical Research · doi:10.1023/a:1018879331061 · Cited by 104
Recent advances in liposomal dry powder formulations: preparation and evaluation
Misra, A. R., Jinturkar, K., Patel, D. H., Lalani, J., & Chougule, M. B. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802652309 · Cited by 104
Alternative carriers in dry powder inhaler formulations
Rahimpour, Y., Kouhsoltani, M., & Hamishehkar, H. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.013 · Cited by 99
The DiskusTM: a review of its position among dry powder inhaler devices
Chrystyn, H. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01382.x · Cited by 98
Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery
Yang, Z., Chen, X., Huang, W., Wong, B. C. K., Yin, L., Wong, I. Y. F., & Xu (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s28011 · Cited by 97
Formulation and Characterization of Lipid-Coated Tobramycin Particles for Dry Powder Inhalation
Pilcer, G., Sebti, T., & Amighi, K. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9789-4 · Cited by 94
Park, C., Li, X., Vogt, F. G., Hayes, D., Zwischenberger, J. B., Park, E., & Mansour, H. M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.06.047 · Cited by 94
Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs
Newman, S. P., Pitcairn, G. R., Hirst, P. H., & Rankin, L. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00081-4 · Cited by 93
Effect of carrier particle shape on dry powder inhaler performance
Kaialy, W., Alhalaweh, A., Velaga, S. P., & Nokhodchi, A. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.09.010 · Cited by 91
The use of computational approaches in inhaler development
Wong, W., Fletcher, D. F., Traini, D., Chan, H., & Young, P. M. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.004 · Cited by 89
Effervescent dry powder for respiratory drug delivery
Ely, L., Roa, W., Finlay, W. H., & Löbenberg, R. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.10.021 · Cited by 87
Schulte, M. M., Osseiran, K., Betz, R., Wencker, M., Brand, P., Meyer, T. S., & Haidl, P. (2008) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2007.0634 · Cited by 85
Shur, J., Lee, S., Adams, W. P., Lionberger, R. A., Tibbatts, J., & Price, R. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9379-9 · Cited by 85
Irngartinger, M., Camuglia, V., Damm, M., Goede, J., & Frijlink, H. W. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.016 · Cited by 80
Self-citationMuscarinic receptors on airway mesenchymal cells: Novel findings for an ancient target
Meurs, H., Dekkers, B. G. J., Maarsingh, H., Halayko, A. J., Zaagsma, J., & Gosens, R. (2012) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.07.003 · Cited by 80
Serra-Batllés, J., Plaza, V., Badiola, C., & Morejón, E. (2002) · Journal of Aerosol Medicine · doi:10.1089/08942680252908584 · Cited by 80
Inhaler technique and patient's preference for dry powder inhaler devices
Lavorini, F., & Fontana, G. A. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.846907 · Cited by 79
The Evolution of Inhaler Technology
Grossman, J. (1994) · Journal of Asthma · doi:10.3109/02770909409056770 · Cited by 78
Technosphere® Insulin: Defining the Role of Technosphere Particles at the Cellular Level
Angelo, R., Rousseau, K., GRANT, M. L., Leone‐Bay, A., & Richardson, P. C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300320 · Cited by 77
van Drooge, D. J., Hinrichs, W. L. J., Dickhoff, B. H. J., Elli, M., Visser, M. R., Zijlstra, G. S., & Frijlink, H. W. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.06.007 · Cited by 73
Self-citationCassidy, J., Amin, N., Marino, M. T., Gotfried, M. H., Meyer, T. S., Sommerer, K., & Baughman, R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0443-4 · Cited by 71
Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres
Sakagami, M., Sakon, K., Kinoshita, W., & Makino, Y. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00475-8 · Cited by 69
Devices and formulations for pulmonary vaccination
Tonnis, W. F., Lexmond, A. J., Frijlink, H. W., de Boer, A. H., & Hinrichs, W. L. J. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.810622 · Cited by 67
Self-citationMueannoom, W., Srisongphan, A., Taylor, K. M. G., Hauschild, S., & Gaisford, S. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.09.016 · Cited by 65
Preference, satisfaction and errors with two dry powder inhalers in patients with COPD
van der Palen, J. A. M., Ginko, T., Kroker, A., van der Valk, P., Goosens, M., Padullés, L., Seoane, B., Rekeda, L., & Gil, E. G. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.808186 · Cited by 63
Hoppentocht, M., Hagedoorn, P., Frijlink, H. W., & de Boer, A. H. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.10.019 · Cited by 63
Self-citationNaikwade, S. R., Bajaj, A., Gurav, P. B., Gatne, M. M., & Soni, P. S. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9290-6 · Cited by 59
Zhou, Q. T., Morton, D. A. V., Yu, H. H., Jacob, J., Wang, J., Li, J., & Chan, H. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23685 · Cited by 56
Preparation of sustained release rifampicin microparticles for inhalation
Son, Y., & McConville, J. T. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01531.x · Cited by 45
Comté, L., Vrijens, B., Tousset, E., Gérard, P., & Urquhart, J. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9058-0 · Cited by 41
Muscarinic receptors in human airways
White, M. V. (1995) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(95)70209-1 · Cited by 38
Use of budesonide Turbuhaler in young children suspected of asthma
Bisgaard, H. F., Pedersen, S., & Nikander, K. (1994) · European Respiratory Journal · doi:10.1183/09031936.94.07040740 · Cited by 31
Swaminathan, J., Gobbo, O. L., Tewes, F., Healy, A. M., & Ehrhardt, C. (2013) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2013.1049 · Cited by 31
Bouchard, A., Jovanović, N., DEBOER, A., Martín, Á., Jiskoot, W., Crommelin, D. J. A., Hofland, G. W., & Witkamp, G. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.03.020 · Cited by 23
Self-citationExperimental investigation of design parameters on dry powder inhaler performance
Ngoc, N. T. Q., Chang, L., Jia, X., & Lau, R. W. M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.08.072 · Cited by 16
Device Factors Affecting Pulmonary Delivery of Dry Powders
Smutney, C., GRANT, M. L., & Kinsey, P. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.77 · Cited by 8
Cited by
Dry powder inhalation: past, present and future
de Boer, A. H., Hagedoorn, P., Hoppentocht, M., Buttini, F., Grasmeijer, F., & Frijlink, H. W. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1224846 · Cited by 271
Self-citationJeong, J.-H., Lee, H.-S., Choi, J.-C., Kang, J.-H., Kim, D.-W., Park, C.-S., & Park, C.-W. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s511099 · Cited by 5
Metadata
- Authors
- Hoppentocht, M., Hagedoorn, P., Frijlink, H. W., & de Boer, A. H.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 75
- Pages
- 18-31
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2103984901
- Cited by
- 303
- References
- 79
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.